280 related articles for article (PubMed ID: 29973405)
1.
Wu L; Bernal GM; Cahill KE; Pytel P; Fitzpatrick CA; Mashek H; Weichselbaum RR; Yamini B
Sci Transl Med; 2018 Jul; 10(448):. PubMed ID: 29973405
[TBL] [Abstract][Full Text] [Related]
2. Regulation of temozolomide resistance in glioma cells via the RIP2/NF-κB/MGMT pathway.
Hu YH; Jiao BH; Wang CY; Wu JL
CNS Neurosci Ther; 2021 May; 27(5):552-563. PubMed ID: 33460245
[TBL] [Abstract][Full Text] [Related]
3. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
Chen Z; Wei X; Shen L; Zhu H; Zheng X
Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of NF-κB results in anti-glioma activity and reduces temozolomide-induced chemoresistance by down-regulating MGMT gene expression.
Yu Z; Chen Y; Wang S; Li P; Zhou G; Yuan Y
Cancer Lett; 2018 Aug; 428():77-89. PubMed ID: 29705182
[TBL] [Abstract][Full Text] [Related]
5. ATRX/EZH2 complex epigenetically regulates FADD/PARP1 axis, contributing to TMZ resistance in glioma.
Han B; Meng X; Wu P; Li Z; Li S; Zhang Y; Zha C; Ye Q; Jiang C; Cai J; Jiang T
Theranostics; 2020; 10(7):3351-3365. PubMed ID: 32194873
[No Abstract] [Full Text] [Related]
6. Transcriptional control of O
Happold C; Stojcheva N; Silginer M; Weiss T; Roth P; Reifenberger G; Weller M
J Neurochem; 2018 Mar; 144(6):780-790. PubMed ID: 29480969
[TBL] [Abstract][Full Text] [Related]
7. Decoy Receptor DcR1 Is Induced in a p50/Bcl3-Dependent Manner and Attenuates the Efficacy of Temozolomide.
Mansour NM; Bernal GM; Wu L; Crawley CD; Cahill KE; Voce DJ; Balyasnikova IV; Zhang W; Spretz R; Nunez L; Larsen GF; Weichselbaum RR; Yamini B
Cancer Res; 2015 May; 75(10):2039-48. PubMed ID: 25808868
[TBL] [Abstract][Full Text] [Related]
8. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J
Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149
[TBL] [Abstract][Full Text] [Related]
9. Gene expression profiling predicts response to temozolomide in malignant gliomas.
Yoshino A; Ogino A; Yachi K; Ohta T; Fukushima T; Watanabe T; Katayama Y; Okamoto Y; Naruse N; Sano E; Tsumoto K
Int J Oncol; 2010 Jun; 36(6):1367-77. PubMed ID: 20428759
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study.
Boccard SG; Marand SV; Geraci S; Pycroft L; Berger FR; Pelletier LA
Oncotarget; 2015 Oct; 6(30):29456-68. PubMed ID: 26336131
[TBL] [Abstract][Full Text] [Related]
11. miR-140 targeting CTSB signaling suppresses the mesenchymal transition and enhances temozolomide cytotoxicity in glioblastoma multiforme.
Ho KH; Cheng CH; Chou CM; Chen PH; Liu AJ; Lin CW; Shih CM; Chen KC
Pharmacol Res; 2019 Sep; 147():104390. PubMed ID: 31398406
[TBL] [Abstract][Full Text] [Related]
12. β-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species.
Bi Y; Li H; Yi D; Bai Y; Zhong S; Liu Q; Chen Y; Zhao G
Cancer Lett; 2018 Oct; 435():66-79. PubMed ID: 30081068
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of BASP1 Promotes Temozolomide Resistance in Gliomas via Epigenetic Activation of the FBXO32/NF-κB/MGMT Axis.
Liao X; Li Z; Zheng H; Qian W; Zhang S; Chen S; Li X; Tang M; Xu Y; Yu R; Li M; Song L; Li J
Mol Cancer Res; 2023 Jul; 21(7):648-663. PubMed ID: 36961398
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of ABCE1 inhibits temozolomide resistance in glioma through the PI3K/Akt/NF-κB signaling pathway.
Zhang P; Chen XB; Ding BQ; Liu HL; He T
Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30455394
[TBL] [Abstract][Full Text] [Related]
15. Correlations of MGMT genetic polymorphisms with temozolomide resistance and prognosis of patients with malignant gliomas: a population-based study in China.
Wang HW; Xu ZK; Song Y; Liu YG
Cancer Gene Ther; 2017 May; 24(5):215-220. PubMed ID: 28409559
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas.
Ishii D; Natsume A; Wakabayashi T; Hatano H; Asano Y; Takeuchi H; Shimato S; Ito M; Fujii M; Yoshida J
Neurol Med Chir (Tokyo); 2007 Aug; 47(8):341-9; discussion 350. PubMed ID: 17721049
[TBL] [Abstract][Full Text] [Related]
17. Circ_0005198 enhances temozolomide resistance of glioma cells through miR-198/TRIM14 axis.
Deng Y; Zhu H; Xiao L; Liu C; Meng X
Aging (Albany NY); 2020 Dec; 13(2):2198-2211. PubMed ID: 33316781
[TBL] [Abstract][Full Text] [Related]
18. Effect of IFN-beta on human glioma cell lines with temozolomide resistance.
Yoshino A; Ogino A; Yachi K; Ohta T; Fukushima T; Watanabe T; Katayama Y; Okamoto Y; Naruse N; Sano E
Int J Oncol; 2009 Jul; 35(1):139-48. PubMed ID: 19513561
[TBL] [Abstract][Full Text] [Related]
19. Low c-Met expression levels are prognostic for and predict the benefits of temozolomide chemotherapy in malignant gliomas.
Li MY; Yang P; Liu YW; Zhang CB; Wang KY; Wang YY; Yao K; Zhang W; Qiu XG; Li WB; Peng XX; Wang YZ; Jiang T
Sci Rep; 2016 Feb; 6():21141. PubMed ID: 26879272
[TBL] [Abstract][Full Text] [Related]
20. Magnolol and Temozolomide exhibit a synergistic anti-glioma activity through MGMT inhibition.
Kundu M; Das S; Nandi S; Dhara D; Mandal M
Biochim Biophys Acta Mol Basis Dis; 2023 Oct; 1869(7):166782. PubMed ID: 37286145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
